How Does HPV Increase Cancer Risk in Cells?
Persistent viral infections such as human papillomavirus elevate oncogenic risk primarily by expressing viral oncoproteins that disable fundamental host tumor suppressor pathways. When high-risk viral strains persist without host clearance, sustained expression of viral genes leads to cell cycle deregulation, impaired DNA damage repair, genomic instability, and resistance to apoptosis. Over time, these combined molecular alterations transform normal infected epithelial cells into malignant phenotypes, driving tumorigenesis.
Viral Persistence and Genomic Integration
Most transient papillomavirus infections are effectively resolved by the host immune response. However, chronic persistence enables high-risk strains (notably HPV-16 and HPV-18) to maintain long-term reservoirs in the basal epithelial layer.
In many progressive lesions, persistent episomal viral DNA integrates into the host cell genome. This integration event frequently disrupts the viral regulatory gene E2, which normally acts as a transcriptional repressor of the early promoter. The loss of E2-mediated negative feedback results in unchecked and sustained overexpression of the primary viral oncoproteins: E6 and E7.
Inactivation of Key Tumor Suppressors: E6 and E7
The primary drivers of HPV-induced oncogenesis are the viral oncoproteins E6 and E7, which target central regulatory nodes of the cell cycle:
- E6 and p53 Degradation: The E6 oncoprotein recruits host ubiquitin ligase E6AP (E6-associated protein). This complex binds to the tumor suppressor p53 and targets it for degradation via the ubiquitin-proteasome system. Loss of functional p53 impairs DNA damage checkpoints and inhibits the activation of downstream pro-apoptotic factors such as Bax and PUMA, allowing cells with genetic mutations to survive and divide.
- E7 and Retinoblastoma (pRb) Inactivation: The E7 oncoprotein binds to the retinoblastoma protein (pRb), disrupting its interaction with the E2F family of transcription factors. Free E2F promotes the transcription of genes necessary for the \(G_1 \to S\) phase transition, forcing host cells into unscheduled DNA synthesis even in the absence of external growth signals.
Genomic Instability and Secondary Mutations
While the inactivation of p53 and pRb removes critical cell cycle brakes, viral oncoprotein expression alone is generally insufficient for complete malignant transformation. Instead, it creates an environment permissive to progressive genetic damage:
- Centrosome Amplification: E7 induces abnormal centrosome duplication, leading to multipolar mitotic spindles and frequent chromosome missegregation (aneuploidy).
- Impaired DNA Repair: Degradation of p53 eliminates the cell's ability to arrest division in the presence of double-strand breaks, allowing structural chromosomal rearrangements to persist.
- Telomerase Activation: E6 upregulates human telomerase reverse transcriptase (hTERT), preventing critical telomere shortening and conferring cellular replicative immortality.
Progression to Malignancy
Accumulation of somatic mutations alongside sustained viral oncoprotein signaling ultimately drives the progression from low-grade intraepithelial lesions to invasive carcinoma. Persistent viral infection serves as an essential oncogenic driver by continuously disabling cell cycle checkpoints and immune surveillance mechanisms, thereby accelerating cellular evolution toward a fully transformed, malignant state.